November 20th 2024
“How do we personalize and improve patient selection for frontline treatment now that patients are living, on average, more than 2 years with this aggressive cancer?” said David H. Aggen, MD, PhD
What Immunotherapy Combination Is Best in Metastatic Bladder Cancer?
November 15th 2018Extended follow-up from the CheckMate 032 trial showed strong results with three different immunotherapy regimens involving nivolumab and ipilimumab in patients with previously treated metastatic urothelial carcinoma.
Evaluating Two RT-Plus-Chemotherapy Strategies in Bladder Cancer Patients Undergoing Bladder Surgery
March 7th 2018In this interview, we spoke with John J. Coen, MD, a radiation oncologist who presented results at the 2018 Genitourinary Cancers Symposium of a phase II study exploring two different radiation-plus-chemotherapy combination strategies in patients undergoing bladder surgery for their tumors.
Is This Patient With Metastatic Bladder Cancer a Candidate for Second-Line Immunotherapy Treatment?
A 67-year-old man, a former smoker, presented with gross hematuria. A CT urogram showed a bladder tumor in the anterior wall and multiple enlarged retroperitoneal lymph nodes. Two vertebral metastases were seen on a bone scan. He underwent a transurethral resection of the bladder, and the pathology report revealed muscle-invasive urothelial carcinoma.